Calls for papers
-
An article in the January 31, 2011 issue of PNAS describes how rhesus macaques gained protection against the measles virus after inhalation of a single dose of a dry powder live attenuated measles vaccine (LAMV).… Read more . . .
-
AstraZeneca has announced that it has received marketing authorization from the European Commission for its Fluenz nasal spray vaccine for the prevention of seasonal flu in children under 18 years old down to 24 months… Read more . . .
-
A severe winter storm has necessitated postponement of Gateway Analytical’s grand opening ceremony from February 1 to April 12. Gateway is a subsidiary of ChemImage and offers particle analysis services including ingredient-specific particle sizing for… Read more . . .
-
Assuming that MAP Pharmaceuticals’ Levadex inhaled dihydroergotamine for the treatment of migraine receives FDA approval, Allergan will market the product to pain specialists and neurologists in the US. MAP will handle marketing to primary care… Read more . . .
-
According to BASF, its new Ultraform N2320 003 PRO plastic for injection molding is specifically designed for medical applications with highly-stressed components, including dry powder inhalers. The new plastic will become commercially available in February… Read more . . .
-
California-based biotech company Ligand Pharmaceuticals has acquired CyDex Pharmaceuticals and its Captisol solubility-enhancing technology. CyDex’s pipeline includes a Captisol-enhanced budesonide/azelastine nasal spray. Ligand will operate CyDex as a wholly-owned subsidiary. Read the company’s press release. Read more . . .
-
A court in The Hague has ruled in favor of Sandoz and Hexal, both units of Novartis, agreeing that the Dutch portion of GSK’s European patent for Advair is not valid. GSK may appeal the… Read more . . .
-
The UK National Health Service has announced that a new MDI spacer developed through Health Enterprise East (HEE), an NHS "innovation hub," will be available through Vivo Smart Medical Devices. The collapsible spacer, called the… Read more . . .
-
MannKind Corporation has again received a complete response letter from the FDA in regards to its application for Afrezza inhaled insulin. A previous CRL was issued in March 2010, and the company resubmitted the NDA… Read more . . .
-
According to Alexza Pharmaceuticals, it plans to resubmit its NDA for AZ-004 (Staccato loxapine) for the treatment of agitation in schizophrenic patients in July 2011. The company received a complete response letter (CRL) for the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden